JP2021528407A - 組合せ遺伝子治療薬 - Google Patents

組合せ遺伝子治療薬 Download PDF

Info

Publication number
JP2021528407A
JP2021528407A JP2020570467A JP2020570467A JP2021528407A JP 2021528407 A JP2021528407 A JP 2021528407A JP 2020570467 A JP2020570467 A JP 2020570467A JP 2020570467 A JP2020570467 A JP 2020570467A JP 2021528407 A JP2021528407 A JP 2021528407A
Authority
JP
Japan
Prior art keywords
transgene
vector
based vector
therapeutic agent
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528407A5 (https=
Inventor
サミル・エル・アンダロッシ
ペル・ルンディン
Original Assignee
エヴォックス・セラピューティクス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヴォックス・セラピューティクス・リミテッド filed Critical エヴォックス・セラピューティクス・リミテッド
Publication of JP2021528407A publication Critical patent/JP2021528407A/ja
Publication of JP2021528407A5 publication Critical patent/JP2021528407A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Manufacturing & Machinery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020570467A 2018-06-22 2019-06-21 組合せ遺伝子治療薬 Pending JP2021528407A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810301.0A GB201810301D0 (en) 2018-06-22 2018-06-22 Combinatorial gene therapy
GB1810301.0 2018-06-22
PCT/EP2019/066471 WO2019243574A1 (en) 2018-06-22 2019-06-21 Combinatorial gene therapy

Publications (2)

Publication Number Publication Date
JP2021528407A true JP2021528407A (ja) 2021-10-21
JP2021528407A5 JP2021528407A5 (https=) 2022-06-24

Family

ID=63042788

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020570467A Pending JP2021528407A (ja) 2018-06-22 2019-06-21 組合せ遺伝子治療薬

Country Status (14)

Country Link
US (1) US20210252164A1 (https=)
EP (1) EP3810206B1 (https=)
JP (1) JP2021528407A (https=)
KR (1) KR20210024040A (https=)
CN (1) CN112955185A (https=)
AU (1) AU2019289998A1 (https=)
BR (1) BR112020026260A2 (https=)
CA (1) CA3104432A1 (https=)
GB (1) GB201810301D0 (https=)
IL (1) IL279584A (https=)
MX (1) MX2020013865A (https=)
SG (1) SG11202012727SA (https=)
WO (1) WO2019243574A1 (https=)
ZA (1) ZA202100244B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022315530A1 (en) 2021-07-20 2024-01-18 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513928A (ja) * 2011-03-11 2014-06-19 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 無カプシドａａｖベクター、組成物ならびにベクター製造および遺伝子運搬のための方法
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
JP2017526388A (ja) * 2014-09-05 2017-09-14 エクサーカイン コーポレイションＥｘｅｒｋｉｎｅ Ｃｏｒｐｏｒａｔｉｏｎ エキソソームの単離
WO2017172606A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitability
JP2021507682A (ja) * 2017-11-08 2021-02-25 エヴォックス・セラピューティクス・リミテッド Ｒｎａ治療薬を含むエクソソーム

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273150A1 (en) * 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN102813942A (zh) * 2012-08-15 2012-12-12 钟志容 脂质超声微泡介导的腺相关病毒基因转染制剂及制备工艺
EP3842537A1 (en) * 2013-12-30 2021-06-30 CureVac AG Artificial nucleic acid molecules
WO2016044947A1 (en) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes useful to treat lysosomal storage disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513928A (ja) * 2011-03-11 2014-06-19 アソシアシオン・アンスティテュ・ドゥ・ミオロジー 無カプシドａａｖベクター、組成物ならびにベクター製造および遺伝子運搬のための方法
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
JP2017526388A (ja) * 2014-09-05 2017-09-14 エクサーカイン コーポレイションＥｘｅｒｋｉｎｅ Ｃｏｒｐｏｒａｔｉｏｎ エキソソームの単離
WO2017172606A1 (en) * 2016-03-28 2017-10-05 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitability
JP2021507682A (ja) * 2017-11-08 2021-02-25 エヴォックス・セラピューティクス・リミテッド Ｒｎａ治療薬を含むエクソソーム

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL MOL NEUROBIOL., vol. 36, JPN6023024462, 2016, pages 417427, ISSN: 0005268664 *
MOL THER: METHODS & CLINICAL DEVELOPMENT, vol. 9, JPN6023024463, June 2018 (2018-06-01), pages 278 - 287, ISSN: 0005268663 *

Also Published As

Publication number Publication date
CA3104432A1 (en) 2019-12-26
BR112020026260A2 (pt) 2021-03-23
IL279584A (en) 2021-03-01
KR20210024040A (ko) 2021-03-04
EP3810206A1 (en) 2021-04-28
ZA202100244B (en) 2022-07-27
GB201810301D0 (en) 2018-08-08
US20210252164A1 (en) 2021-08-19
EP3810206B1 (en) 2024-01-24
SG11202012727SA (en) 2021-01-28
WO2019243574A1 (en) 2019-12-26
AU2019289998A1 (en) 2021-02-04
CN112955185A (zh) 2021-06-11
MX2020013865A (es) 2021-03-25

Similar Documents

Publication Publication Date Title
JP2021528407A (ja) 組合せ遺伝子治療薬
JP7381494B2 (ja) 転写調節要素及びその使用
JP7208231B2 (ja) 肺組織への標的化薬物及び遺伝子送達のためのシンシチンの使用
US20240207452A1 (en) Novel compositions with brain-specific targeting motifs and compositions containing same
TW201837170A (zh) 新穎ａａｖ媒介的流感疫苗
KR20220070075A (ko) 아데노-관련 바이러스 변이체 캡시드 및 그 용도
US20100266551A1 (en) Adeno-associated viral vectors for the expression of dysferlin
US12467066B2 (en) Compositions and methods for treating retinal disorders
CN114072129A (zh) 可用于治疗异染性脑白质营养不良的组合物
KR20220107243A (ko) Apoe 유전자 요법
JP2023524414A (ja) Ｔｄｐ－４３プロテイノパチーの処置のための組成物および方法
KR20230131223A (ko) 리간드와 생리 활성을 갖는 단백질의 융합 단백질을코딩하는 유전자가 짜넣어진 핵산 분자
US20180099029A9 (en) Serca2 therapeutic compositions and methods of use
US20230089121A1 (en) Novel combination of nucleic acid regulatory elements and methods and uses thereof
JP2023515442A (ja) 筋肉特異的核酸調節エレメント及びその方法と使用
WO2020176732A1 (en) TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY
TW202306589A (zh) 用於改進治療ｘ連鎖肌微管性肌病之組成物及方法
JP2005518807A (ja) 筋細胞中の目的とする遺伝子の発現の持続のための発現カセット
CA3193685A1 (en) Recombinant adeno-associated viruses for cns or muscle delivery
RU2748383C1 (ru) Способ терапии болезни Тея-Сакса и болезни Сандхоффа с помощью генетически модифицированных мезенхимных стволовых клеток человека со сверхэкспрессией β-гексозаминидазы A
US20240342313A1 (en) Vector encoding rod-derived cone viability factor and human igk signal sequence
WO2024216096A1 (en) Cd46 binding vectors and uses thereof to treat cns disorders
WO2024236032A1 (en) Gene therapies for phenylketonuria
TW202449149A (zh) 用於治療與葡萄糖神經醯胺酶β１缺陷相關之神經病症的組合物及方法
HK40030486B (en) Compositions and methods for treating retinal disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241007